Medical News

RSS

PlusNews reports on importance of cost-effectiveness of ZAMSTAR study for policymakers, donors amid economic downturn

PlusNews reports on the results of the Zambia-South Africa TB and AIDS Reduction (ZAMSTAR) study released on Monday at the International Lung Health Conference in Lille, France, which show that "home-based tuberculosis (TB) education and testing reduced community TB prevalence by about 20 percent."

4 Nov 2011

Scientists discover neurons responsible for light-induced arousal response

Bright light arouses us. Bright light makes it easier to stay awake. Very bright light not only arouses us but is known to have antidepressant effects. Conversely, dark rooms can make us sleepy. It's the reason some people use masks to make sure light doesn't wake them while they sleep.

4 Nov 2011

Escitalopram reduces pain severity, interference in opioid-dependent patients

In what is believed to be the first study of its kind to demonstrate an association between the antidepressant escitalopram and improved general pain, researchers from Boston University School of Medicine (BUSM), have found that opioid-dependent patients treated with escitalopram experienced meaningful reductions in pain severity and pain interference during the first three months of therapy.

4 Nov 2011

Penn research group receives NCI grant to establish BETRNet

A research group at the Perelman School of Medicine of the University of Pennsylvania, led by John Lynch, MD, PhD, assistant professor of Medicine in the Division of Gastroenterology, has received a National Cancer Institute (NCI) grant to establish a Barrett's esophagus translational research network (BETRNet) with Columbia University and the Mayo Clinic.

4 Nov 2011

FDA accepts VIVUS' Qnexa NDA for filing and review

VIVUS, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the New Drug Application (NDA) for Qnexa to treat obesity. The company resubmitted the NDA on October 17, 2011.

4 Nov 2011

Final results from Vertex KALYDECO second of two Phase 3 studies on CF

Vertex Pharmaceuticals Incorporated today announced final results from the ENVISION study, the second of two pivotal Phase 3 studies of KALYDECO, a medicine in development that targets the defective protein that causes cystic fibrosis.

4 Nov 2011

Scientists identify gene responsible for abdominal aortic aneurysms

Medical scientists have for the first time identified a gene responsible for a fatal abdominal condition that afflicts tens of thousands of people across the world.

4 Nov 2011

Bristol-Myers Squibb, ASLAN partner to develop BMS-777607 for solid tumors

ASLAN Pharmaceuticals Pte Ltd, a pharmaceutical company headquartered in Singapore, and Bristol-Myers Squibb Company today announced an innovative strategic partnership allowing for the rapid development of BMS-777607, Bristol-Myers Squibb's investigational small molecule inhibitor of the MET receptor tyrosine kinase for treatment of solid tumors.

4 Nov 2011

Evolutionary 'breakpoints' on chromosomes may lead to canine cancer

North Carolina State University researchers have uncovered evidence that evolutionary "breakpoints" on canine chromosomes are also associated with canine cancer. Mapping these "fragile" regions in dogs may also have implications for the discovery and treatment of human cancers.

4 Nov 2011

Climate change, environmental destruction threaten improvements among world's poorest, UNDP report warns

"Unchecked environmental destruction will halt -- or even reverse -- the huge improvements seen in the living conditions of the world's poorest people in recent decades," the United Nations Development Programme (UNDP) warns in its 2011 Human Development report, which was released on Wednesday, the Guardian reports.

4 Nov 2011

A prescription for prevention

Medicine-related hospital admissions could be reduced by a simple initiative designed and implemented by researchers at the University of Sydney’s Faculty of Pharmacy.

4 Nov 2011

Using sub-nanometre cages to identify molecules

Reliable and accurate single-molecule medical diagnosis is a step closer to reality with the development a new technique by Cambridge University researchers which uses sub-nanometre “cages” to capture and identify molecules.

3 Nov 2011

Young woman gets double hand transplant

In a surgical feat a 28 year old woman who lost her hands and feet to an infection about four years ago is recuperating after undergoing a double hand transplant.

3 Nov 2011

Merck’s cholesterol lowering drug gets FDA panel’s vote

A health advisors’ panel have unanimously backed the use of Merck & Co's cholesterol-lowering drug Vytorin for preventing stroke and other heart problems in patients with chronic kidney disease, but only in those patients not yet on dialysis. The panel voted 16-0 during a meeting today in Silver Spring, Maryland.

3 Nov 2011

Loneliness can affect sleep: Sleep

A new study from the American Academy of Sleep Medicine published in the Nov. 1 issue of the journal Sleep, suggests that loneliness could be significantly associated with sleep fragmentation, but not sleep duration or subjective sleep measures.

3 Nov 2011

Edwards Life Sciences heart valve approved in the US

The U.S. Food and Drug Administration (FDA) this Wednesday approved the sale of Edwards Life Sciences Corp's Sapien heart valve for patients deemed too sick to have open-heart surgery.

3 Nov 2011

Slowing aging by cleaning away old cells: Study

Researchers have found a novel way of reversing the aging process. They found that a special category of cells, known as senescent cells, are bad actors that promote the aging of the tissues. Cleansing the body of the cells, they hope, could postpone many of the diseases of aging. This could pave the way for drugs that would keep human tissues healthier longer, but it is unclear until further testing is done whether such drugs could eventually help people live longer.

3 Nov 2011

Cancer cells maintain rapid proliferation due to PK-M2 enzyme

Cancer cells maintain their life-style of extremely rapid growth and proliferation thanks to an enzyme called PK-M2 (pyruvate kinase M2) that alters the cells' ability to metabolize glucose - a phenomenon known as the Warburg effect.

3 Nov 2011

Savient third quarter net loss decreases to $27.4 million

Savient Pharmaceuticals, Inc. reported financial results for the three and nine months ended September 30, 2011, which reflect the Company's continuing investment in the U.S. launch of KRYSTEXXA (pegloticase). Savient ended the quarter with $202.7 million in cash and short-term investments, a decrease of $37.6 million for the quarter.

3 Nov 2011

The brain and the heart may not be so different after all

What do heart disease and dementia have in common? Perhaps more than meets the eye, according to researchers at the University of Rochester Medical Center.

3 Nov 2011